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Sickle cell anemia is a common and disabling disorder profoundly aﬀecting mortality as well as quality of life. Up to 35% of men
with sickle cell disease are aﬀected by painful, prolonged erections termed ischemic priapism. A priapic episode may result in
ﬁbrosis and permanent erectile dysfunction. The severity of sickle cell disease manifestations is variable dependent on a number
of contributing genetic factors; however, priapism tends to cluster with other severe vascular complications including pulmonary
hypertension, leg ulceration, and overall risk of death. The mechanisms underlying priapism in sickle cell disease have begun to
be elucidated including hemolysis-mediated dysregulation of the nitric oxide signaling pathway and dysregulation of adenosine-
mediated vasodilation. A better understanding of these mechanisms is leading toward novel preventative strategies. This paper
will focus on the mechanisms underlying development of ischemic priapism in sickle cell disease, current acute and preventative
treatment strategies, and future directions for improved management of this disorder.
1.Introduction
Sickle cell disease (SCD) is a common disorder with 8% of
African Americans heterozygous for the hemoglobin S point
mutation (HbS) in the β-globin gene and approximately
50,000 Americans homozygous for this mutation [1, 2].
Hemoglobin is a tetrameric protein composed of two α-
chains and two β-globin chains. Deoxygenation results in
aggregationandpolymerizationofHbStetramers,formation
of needle-like hemoglobin ﬁbers, and distortion of red cells
into the characteristic sickle shape.
Sickling is dependent on multiple variables including
hemoglobin concentration and hydration status, pH and
degree of deoxygenation. Sickling is more common in
vascular beds with low-ﬂow states including the splenic
sinusoids, the bone marrow, the penile corpora during an
erection, or any inﬂamed tissue. The combined inﬂuence of
these factors can result in a vicious cycle of inﬂammation,
hypoxia, and acidosis resulting in increased sickling, vessel
occlusion, and ischemia [3].
Manifestations of SCD are widespread and generally
secondary to ischemia from vessel occlusion and hemolysis
from direct rupture of sickle cells that have lost normal red
cell deformability. The type and severity of complications
vary signiﬁcantly between individuals. Common manifes-
tations include vaso-occlusive crises, the result of hypoxic
injury or infarction, which may aﬀect the brain, pulmonary
vessels, spleen, bone marrow, kidney, retina, penis or other
tissues resulting in sequelae such acute chest syndrome with
pulmonary infarction, stroke or splenic infarction. Splenic
infarction and subsequent ﬁbrosis ultimately contribute to
increased susceptibility to infections from encapsulated bac-
teria leading to increased risk of septicemia and meningitis,
the most common causes of death in children with SCD. Leg
ulcers are another common manifestation of vaso-occlusion.
A comprehensive discussion of the manifestations of SCD is
beyond the scope of this paper.
This paper will focus on one common manifestation
that can signiﬁcantly aﬀect quality of life of men with SCD,
which is the development of prolonged, painful erections
known as low-ﬂow or ischemic priapism that result in
tissue ischemia and attenuated or absent return of functional
erections. Reports of the lifetime prevalence of ischemic
priapism in SCD range from 2–35% [4, 5]. High ﬂow2 Anemia
priapism,whichresultsfromincreasedarterialﬂowgenerally
caused by trauma, does not result in tissue ischemia and
has not been associated with increased risk in SCD patients.
The mechanisms underlying high and low-ﬂow priapism
completely diﬀer,asdotheirtreatments;therefore,thispaper
will focus only on ischemic priapism, which is substantially
increased in SCD patients.
2.Pathophysiology ofPriapism
In the ﬂaccid state, the erectile tissue smooth muscle is
tonically contracted as are the arterial and arteriolar vessels,
allowing only a small amount of ﬂow to meet nutritional
needs. When neurotransmitters are released to signal an
erection, there is smooth muscle relaxation resulting in
ﬁlling of the sinusoids and ultimate compression of venous
outﬂow resulting in trapping of blood. This results in an
erection with pressure greater than that of systolic blood
pressure. The corpora cavernosa are covered in a tunica
albuginea, a bilayered structure with an inner layer that
supports the cavernous tissue and an outer layer that runs
longitudinally from the glans to insert onto the pubic rami.
Emissary veins run between the inner and outer layers.
During an erection, these are compressed along with the
subtunical venous plexus to prevent venous outﬂow. The
corpora spongiosum lacks the tunica, and therefore, serves
as an arteriovenous ﬁstula with less rigidity than the corpora
cavernosa [6]. The principal neurotransmitter for erection
is nitric oxide (NO), which is released by both nerve
terminals and endothelial cells. The NO then diﬀuses into
both trabecular cells and arterial smooth muscle cells. This
activates guanylate cyclase, which catalyzes the formation of
cGMP from GTP, and results in a cascade that decreases
intracellular calcium and opens potassium channels to cause
smooth muscle relaxation. Alternative pathways generate
cAMP, which enhances this eﬀect. Detumescence follows
degradation of cGMP and cAMP. cGMP is degraded by
phosphodiesterase-5 (PDE5), the target of sildenaﬁl, varde-
naﬁl and tadalaﬁl.
Stasis and low blood ﬂow rates within the sinusoids of
the erectile tissue make the penis a site at high risk for
developing aveno-occlusive crisis inSCD.Ischemicpriapism
is characterized by a prolonged erection that is usually
painful and not associated with sexual excitement or desire.
Typically, the corpora cavernosa are tense, congested and
tender to palpation while the glans and corpus spongiosum
are usually soft and uninvolved. Classically, the primary
mechanism is thought to be obstruction of venous drainage
resulting in viscous, hypoxic blood [7] leading to interstitial
edema and ﬁbrosis of the cavernosa, ultimately resulting
in impotence. The length of time of ischemia directly
correlates with the likelihood of return of erectile function,
and therefore, ischemic priapism is considered a urologic
emergency. For example, in one study, all patients with
ischemicpriapismepisodesofgreaterthan12hoursduration
had reduction in erectile rigidity. No patients with priapism
g r e a t e rt h a n3 6h o u r sh a dr e t u r no fs p o n t a n e o u sf u n c t i o n a l
erections [4].
3. Mechanisms Underlying Sickle
Cell-InducedPriapism
While anatomic factors and a low-ﬂow state contribute to
making erectile tissue prone to sickle cell-induced pain and
ischemia, abnormal regulation of the nitric oxide (NO)
pathway and its downstream signaling may be particularly
key in the development of priapism and other vascular
complications in SCD.
NO is a potent vasodilator and key to tumescence
as described above, but free NO is readily scavenged in
the blood by hemoglobin. It is converted to nitrate plus
methemoglobin following reaction with oxyhemoglobin
and to iron-nitrosylhemoglobin following reaction with
deoxyhemoglobin [8]. The ability of hemoglobin to scav-
enge NO is normally dramatically reduced by its com-
partmentalization within red blood cells, which creates
a cell-free and therefore hemoglobin-free zone adjacent
to the vessel endothelium due to laminar ﬂow (Figure
1(a)). In addition, the presence of the cell membrane,
cytoskeleton and other factors increase the diﬀusion distance
between NO and hemoglobin. As a result, hemoglobin
contained in red cells has less than 0.2% of the scavenging
capacity of free hemoglobin [9]. The chronic intravascular
hemolysis in SCD changes this tight regulation of NO.
S C Dp a t i e n t sh a v ee l e v a t e df r e eh e m o g l o b i nc o n c e n t r a t i o n s
compared to normal volunteers [8], and these concen-
trations were frequently suﬃcient to blunt vasodilation
in response to nitroprusside administration. Pain crises
may be exacerbated by further hemolysis, NO scaveng-
ing and prevention of vasodilation in the presence of
ischemia.
Other studies have also associated risk for priapism
with markers of hemolysis. Lactate dehydrogenase (LDH),
bilirubin and reticulocyte count were all elevated in men
with SCD who experienced priapism compared with men
with SCD who had never experienced an episode of pri-
apism [10]. In another study, LDH level closely correlated
with the free-hemoglobin level in plasma, accelerated NO
consumption and impaired vasodilation [11]. In addition,
LDH levels in this study could be used to identify a
subset of SCD patients at higher risk for vascular complica-
tions including pulmonary hypertension, priapism, and leg
ulcers.
Chronic scavenging of NO results in a decreased expres-
sion of downstream regulatory molecules including PDE5
that normally degrades cGMP, the second messenger in NO
signaling. Genetically modiﬁed mice homozygous for the
sickle cell mutation (SS−/−) have been shown to express
decreased levels of PDE5 in penile tissue, and similar
eﬀects were seen in mice deﬁcient for endothelial nitric
oxide synthase (eNOS−/−), which also develop priapism
[12]. Nonetheless, following cavernosal nerve stimulation,
these mice express high levels of cavernosal cGMP, likely
secondary to the fact that NO released from nerve terminals
is not as readily scavenged. The combination of chronically
decreased PDE5 and normal cGMP generation following






















































Figure 1: Abnormal nitric oxide signaling leads to priapism in SCD. NO can be readily scavenged by free hemoglobin and deactivated
by conversion to nitrate. This is normally prevented by compartmentalization of hemoglobin in red cells and a cell free zone adjacent to
the endothelium ((a), ﬁrst panel adapted from Liao [9]a n dR o t h e re ta l .[ 23]). In SCD, chronic hemolysis leads to higher levels of free
hemoglobin and decreased NO availability. This results in decreased basal levels of its downstream eﬀector, cGMP, and decreased PDE5,
which degrades cGMP. Following cavernosal nerve stimulation in SCD (b), normal levels of cGMP are achieved as NO is released from
nerve terminals. However, PDE5 levels remain low, leading to prolonged cGMP activity and prolonged erection. This can be prevented by
long-term treatment with sildenaﬁl ((b), second panel). Inhibition of PDE5 by sildenaﬁl results in increased cGMP, which then increases
basal PDE5 levels through normal feedback mechanisms [13, 14].4 Anemia
There is complex regulation of PDE5 by cGMP and
its eﬀector, cGMP-dependent protein kinase (PKG) [13].
cGMP is the substrate for PDE5, but it can also bind at
an additional allosteric site to alter the conformation of
PDE5, exposing a phosphorylation site. This site can be
phosphorylated by PKG, which then increases the activity of
PDE5.Also,asanormalfeedbackmechanism,thepromoters
whichregulatetheexpressionPDE5isoformsfoundinpenile
tissue are responsive to increasing concentrations of cGMP
[14]. That is, cGMP stimulates PDE5 expression to regulate
its own degradation, suggesting that PDE expression could
be enhanced by agents that increase cGMP levels. This
phenomenon has now been demonstrated both in vitro and
in vivo. Culture of cavernous smooth muscle cells treated
with sildenaﬁl increased PDE5 expression, and young but
not old rats treated with sildenaﬁl for 3 weeks demonstrated
an elevation of PDE5 expression in penile tissue following
treatment [15].
The ability of elevated cGMP to stimulate increased
expression of PDE5 has raised the possibility of a novel
preventative strategy for priapism in SCD. While initially
somewhat paradoxical, these results suggest that treatment
of sickle cell patients with PDE5 inhibitors may actually help
prevent priapism by correcting the chronically low levels
of PDE5 in their cavernosal tissue (Figure 1(b)). Indeed,
Burnettandcolleagueswhoposedthishypothesishavefound
thatlong-term,low-dosePDE5inhibitortreatmentmayhelp
reduce priapism in a series of cases [13].
Additional pathways may also aﬀect the development
of priapism in SCD. One that has recently gained interest
is the regulation of adenosine signaling. Similar to NO,
adenosine is a potent vasodilator and neurotransmitter.
Adenosine signals through G-protein coupled receptors
to increase cAMP to result in smooth muscle relaxation,
and intracavernosal injection of adenosine can be used to
induce erection. Studies in adenosine deaminase deﬁcient
mice, which develop prolonged erections, have demon-
strated that excessive adenosine accumulation and adenosine
receptor signaling contribute to priapism through smooth
muscle relaxation [16]. Adenosine signaling was similarly
elevated in the sickle cell SS−/− mouse model. Elevated
levels of adenosine appear to contribute to ﬁbrosis, as
adenosine deaminase enzyme therapy attenuated ﬁbrosis
in both mouse models [17]. These results suggest that
the adenosine signaling pathway may be an excellent tar-
get for the development of new treatment strategies to
prevent priapism or to limit ﬁbrosis following a priapic
episode.
In addition to pathways that regulate vasodilation,
appropriate regulation of vasoconstriction is also necessary
for normal erectile function. RhoA and its downstream
eﬀectors, Rho-kinases (ROCK1 and 2), help maintain the
penisinaﬂaccidstateandhavebeenshowntohaveabnormal
activation in erectile dysfunction [18] including in old age
and diabetes. There is reduced activity of components of this
pathway in both eNOS−/− and SS−/− mice with priapism
[19, 20]. Additional work will be required to further clarify
the role of this pathway in priapism as well as appropriate
targets for therapy.
4.TreatmentStrategies
Acute treatment for ischemic priapism should be instituted
within hours given the increasing likelihood of cavernosal
ﬁbrosis and permanent erectile dysfunction. Standard treat-
ment involves penile blood gas studies, corporeal aspiration,
and phenylephrine injection to induce smooth muscle
contraction and detumescence. SCD patients may beneﬁt
from early high-dose intracavernosal phenylephrine given
that the acidic pH of the ischemic cavernosa may decrease
the aﬃnity of adrenergic receptors for their ligands [21]. If
conservative measures fail, penile shunt surgery should be
performed. This may involve anastamosing corpus spongio-
sum and corpora cavernosa to create an internal ﬁstula. SCD
patientsmayalsobeneﬁtfromhydration,bloodtransfusions,
exchange transfusions, or hyperbaric oxygen.
Ideally, patients at high risk for the development of such
episodes would be identiﬁed early to increase education of
the risks of prolonged priapism and to institute potential
prophylactic strategies. Increased awareness of the signs of
priapism and education on the need for early treatment
may be the best way to prevent longterm sequelae. Despite
the risks of ischemic priapism and its association with
SCD being well known in the medical community, few
men receive education on the need to seek urgent medical
attention for this issue [4]. In addition, it may be possible
to identify the subset of SCD patients at highest risk
for severe priapic episodes for education and prophylatic
strategies before permanent damage has taken place. This
is because prolonged episodes of priapism that result in
intracavernosal ﬁbrosis are often preceded by periods of
“stuttering priapism” (72% of cases in one report [5]) or
acutetransientattacksasoriginallydescribedbyHinman[7].
TreatmentofindividualswithstutteringpriapismwithPDE5
inhibitors has been reported to reduce the frequency of these
episodes [13]. Use of PDE5 inhibitors to abort acute attacks
has also been reported [22], but positive results would be
less likely to be attributable to short-term changes in PDE5
levelsand,infact,suchusecouldpotentiallyworsenapriapic
event [13]. However, it has been hypothesized that use of
PDE5 inhibitors in acute attacks may result in vasodilatation
of cavernosal tissue allowing egress of sickle cells.
There has been evidence to suggest that nocturnal
oxygendesaturation,particularlyinchildren,maycontribute
to the onset of painful crises [24, 25]. This could be
particularlyrelevanttopriapismgiventhenormalphysiology
of nocturnal tumescence, and patients may beneﬁt from
prophylatic treatment including nocturnal oxygen or the use
of continuous positive airway pressure machines.
Hormonal therapy has also been used to decrease
the incidence of priapism [26] including GnRH analogs,
stilbestrol [27] and antiandrogens which are associated with
signiﬁcant side eﬀects including hot ﬂashes and gyneco-
mastia. More recently, one group has investigated the use
o fﬁ n a s t e r i d e ,a5α-reductase inhibitor, to decrease the
frequency of priapism in a population with SCD and
recurrent priapism with a signiﬁcant decrease in the number
of episodes per month [28]. Unfortunately, these hormonal
therapiesmayhavesigniﬁcantorunknowneﬀectsonfertilityAnemia 5
and libido, posing a signiﬁcant disadvantage for use in the
typically young SCD patient population.
Long-term use of oral [29, 30] or intracavernous delivery
[31]o fα-adrenergic agonists has also been investigated with
some success as ﬁrst described by Virag and colleagues.
Digoxin has been used and is believed to exert its eﬀect by
inhibition of the Na/K ATPase pump to prevent relaxation
of cavernosal smooth muscle. Neuromodulatory agents have
also been used, particularly in spinal cord patients, to mod-
erate the autonomic and somatic reﬂex pathways involved
in erection. These include gabapentin, a synthetic analogue
of GABA, an inhibitory neurotransmitter, and baclofen, a
GABA receptor agonist. A detailed paper of these and other
agents in the chronic treatment of ischemic priapism can be
found in a recent paper by Chow and Payne [26].
If irreversible damage has been done, long-term manage-
ment of erectile dysfunction may be treated with placement
of a penile prosthesis to restore function depending on
the preference of the patient, likelihood of success and a
detailed discussion of the risks of the procedure. A severe
and prolonged episode of priapism will result in cavernous
smooth muscle necrosis, ﬁbrosis, and ultimately penile
shortening. If erectile function is unlikely to recover, imme-
diate implantation of a penile prosthesis may, therefore, be
considered to avoid the complications of penile ﬁbrosis and
shortening [32].
The type and severity of the complications of SCD are
variabledependingonavarietyofmodulatinggeneticfactors
including the presence of other types of hemoglobin, par-
ticularly persistent fetal hemoglobin (HbF). Normally after
birth, a switch occurs in the β-globin locus from production
of predominantly γ-globin to β-globin. Hydroxyurea, which
blocks DNA synthesis, has been used to help induce HbF in
the adult, thus helping to reduce the frequency of sickle cell
crises; however, it results in signiﬁcant side eﬀects including
anemia, neutropenia, and renal and liver dysfunction.
5. Conclusions
While the complications associated with the painful crises
associated with sickle cell disease including ischemic pri-
apism remain common and debilitating in the SCD pop-
ulation, a better understanding of the underlying biology
is emerging. There is hope for new preventative treatments
including long-term low-dose PDE5 inhibitors to normalize
NOdownstreamsignalingandpotentialinhibitionofadeno-
sine signaling to minimize ﬁbrosis following an episode of
priapism.
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